CAR-T cell-therapies are commonly indicated as "transformative" therapies referring to the huge expectations associated with them since their market approval in 2017 (USA) and 2018 (Europe). Due to the hopes, but also the enormous prices a horizon scanning (HS) document was first published in 2020 to support budget planning in hospitals. In 2020 13 CAR-T cell-therapies in advanced stages were identified. Of these, in addition to Yescarta® and Kymriah®, that were already approved at that time, three further therapies have since been approved by the European Medicines Agency (EMA) between 8/2020 and 03/2022: Tecartus® (2020), Abcema® (2021) and Breyanzi® (2022).

This HS document updates the earlier report by surveying the status of the ten therapies already described in 2020 and is adding additional therapies that have since then reached a later phase of clinical testing. Within the next year (2023), one new CAR-T cell-Therapy for multiple myeloma will eventually be approved, but further development can be expected with the extension of the approved CAR-T cell-therapies towards earlier lines of therapy and new indications.